179 related articles for article (PubMed ID: 24337692)
1. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series.
Basnayake C; Cash K; Blumbergs P; Limaye V
Clin Rheumatol; 2015 Feb; 34(2):371-7. PubMed ID: 24337692
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
Muñoz-Beamud F; Isenberg DA
Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
[TBL] [Abstract][Full Text] [Related]
4. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
[TBL] [Abstract][Full Text] [Related]
5. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy.
Sultan SM; Ng KP; Edwards JC; Isenberg DA; Cambridge G
Clin Exp Rheumatol; 2008; 26(5):887-93. PubMed ID: 19032824
[TBL] [Abstract][Full Text] [Related]
7. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.
Valiyil R; Casciola-Rosen L; Hong G; Mammen A; Christopher-Stine L
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1328-34. PubMed ID: 20506493
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
10. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients.
Majmudar S; Hall HA; Zimmermann B
J Clin Rheumatol; 2009 Oct; 15(7):338-40. PubMed ID: 20009968
[TBL] [Abstract][Full Text] [Related]
11. Biologics for idiopathic inflammatory myopathies.
Moghadam-Kia S; Aggarwal R; Oddis CV
Curr Opin Rheumatol; 2017 Nov; 29(6):645-651. PubMed ID: 28817464
[TBL] [Abstract][Full Text] [Related]
12. [Biologic agents in myositis: unsolved questions].
Grau JM; Prieto-González S
Med Clin (Barc); 2010 Jul; 135(6):263-4. PubMed ID: 20451933
[No Abstract] [Full Text] [Related]
13. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.
Marie I; Dominique S; Janvresse A; Levesque H; Menard JF
Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877
[TBL] [Abstract][Full Text] [Related]
14. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
Rider LG; Yip AL; Horkayne-Szakaly I; Volochayev R; Shrader JA; Turner ML; Kong HH; Jain MS; Jansen AV; Oddis CV; Fleisher TA; Miller FW
Clin Exp Rheumatol; 2014; 32(5):689-96. PubMed ID: 25068290
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy].
García Hernández FJ; Chinchilla Palomares E; Castillo Palma MJ; González Pulido C; Ocaña Medina C; Sánchez Román J
Med Clin (Barc); 2010 Jul; 135(6):256-9. PubMed ID: 20537666
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroid Monotherapy Is Usually Insufficient Treatment for Idiopathic Inflammatory Myopathy.
Mathur T; Manadan AM; Thiagarajan S; Hota B; Block JA
Am J Ther; 2015; 22(5):350-4. PubMed ID: 23797759
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapy in the idiopathic inflammatory myopathies.
Khoo T; Limaye V
Rheumatol Int; 2020 Feb; 40(2):191-205. PubMed ID: 31680207
[TBL] [Abstract][Full Text] [Related]
18. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
Janardana R; Amin SN; Rajasekhar L; Pinto B; Kodishala C; Selvam S; Shobha V
Rheumatology (Oxford); 2023 Mar; 62(3):1243-1247. PubMed ID: 35946502
[TBL] [Abstract][Full Text] [Related]
19. Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy.
Raghu P; Manadan AM; Schmukler J; Mathur T; Block JA
Am J Ther; 2015; 22(4):244-7. PubMed ID: 25490616
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis.
Alexeeva EI; Valieva SI; Bzarova TM; Semikina EL; Isaeva KB; Lisitsyn AO; Denisova RV; Chistyakova EG
Clin Rheumatol; 2011 Sep; 30(9):1163-72. PubMed ID: 21384257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
